The Economics of Climate Change in the United Republic of Tanzania

Study covers the impacts and economics costs of climate change, the costs of adaptation, and the potential for low carbon growth in Tanzania.

Economics of Climate Change: Kenya

Study covers the impacts and economics costs of climate change, the costs of adaptation, and the potential for low carbon growth in Kenya.

Uncertainty and Climate Change Adaptation: A Scoping Study

The report reviews methods and tools available in the literature on the assessment of climate change uncertainties and reviews existing frameworks for decision making under uncertainty for adaptation to climate change in the Netherlands.

Working Together with Water: A Living Land Builds for Ist Future

Report commissioned by the Dutch government for recommendations on how to protect the Dutch coast and the low-lying hinterland against the consequences of climate change.

Sea-Level Rise: The Impacts and Costs of Sea-Level Rise on Coastal Zones in the EU and the Costs and Benefits of Adaptation

Policy brief which provides an overview of the European-wide assessment of the impacts and economic costs of sea-level rise, and an analysis of the costs and benefits of adaptation.

Adapting to Climate Change: Costs, Benefits, and Modelling Approaches

Summarizes and critically assesses different methodologies and results of literature on the economics of adaptation.

Climate Proofing: A Risk-based Approach to Adaptation

Collection of six case studies in Asia to show why and demonstrate how reducing climate-related risks is an integral part of sustainable development.

The cost-effectiveness of vaccination against lyme disease

Vaccination against Lyme disease appears to be safe and effective; however, the cost per quality-adjusted life-year (QALY) gained with vaccination is unknown. The authors developed a decision-analytical model to evaluate cost-effectiveness of vaccination compared with no vaccination in individuals living in endemic areas of Lyme disease.

Cost-effectiveness of the lyme disease vaccine

A vaccine for Lyme disease was approved in 1998 for use in the US. Given the high cost of the vaccine, the low risk of Lyme disease in many areas, and the largely curable nature of the disease, the cost-effectiveness of the vaccine in various risk groups is uncertain. This study was undertaken to examine the cost-effectiveness of the Lyme disease vaccine and the factors that influence its cost-effectiveness.

Pages